Skip to content

Nektar Therapeutics

US · NKTR #3017 by market cap Listed 1970
30.20 -2.34 -7.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 1.50 In line with history 43rd percentile
5-year average 2.29 · #186 of 513 in Biotechnology
P/E ratio -6.02 Cheap vs history 20th percentile
5-year average -2.93 · forward -3.81
P/S ratio 24.44 Expensive vs history 86th percentile
5-year average 10.95 · forward 37.37 · #226 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Nektar Therapeutics (NKTR) 1.03B -4.88 1.22 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value53.82 Economic moatNone UncertaintyVery High

Trading 78.2% below Morningstar's fair value estimate.

Fair value

Nektar Therapeutics earns a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 31% discount to our quantitative fair value estimate of $53.82 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's valuation metrics strengthen our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 71.0% falls in the top 45% globally. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are undervalued.

The firm's balance sheet is an additional encouraging factor. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio of 10.4, for example, sits in the top 10% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:35 · For reference only, not investment advice and not tailored to your situation.

Nektar Therapeutics discussion 0 comments

Add a comment